Company: AGIO
Filing Date: 2025-05-01
Form Type: 10-Q
Source: 0001439222-25-000036
Chunk: 68

Company: AGIOS PHARMACEUTICALS, INC.
Filing Date: 2025-05-01
Form: 10-Q
Item: Part I, Item 1
Chunk 68
---
 equipment— (39)Non-cash operating lease expense3,018 2,803 Realized gain on investments(2)(152)Changes in operating assets and liabilities:Accounts receivable, net765 (643)Inventory(1,989)(3,994)Prepaid expenses and other current and non-current assets(2,124)(4,091)Accounts payable(2,821)1,430 Accrued expenses and other current liabilities(26,100)(18,038)Income taxes payable(188)— Operating lease liabilities(4,048)(3,649)Net cash used in operating activities(111,489)(99,867)Investing activitiesPurchases of marketable securities(174,903)(244,059)Proceeds from maturities and sales of marketable securities288,256 368,722 Purchases of property and equipment(766)(141)Proceeds from sale of equipment— 40 Net cash provided by investing activities112,587 124,562 Financing activitiesNet proceeds from stock option exercises and employee stock purchase plan1,619 5,864 Net cash provided by financing activities1,619 5,864 Net change in cash and cash equivalents2,717 30,559 Cash and cash equivalents at beginning of the period76,247 88,205 Cash and cash equivalents at end of the period$78,964 $118,764 Supplemental disclosure of non-cash investing and financing transactionsAdditions to property and equipment in accounts payable and accrued expenses$221 $— Net cash taxes (returned) paid$188 $(525)

See accompanying Notes to Condensed Consolidated Financial Statements.

5

AGIOS PHARMACEUTICALS, INC.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

1. Overview and Basis of Presentation

References to AgiosThroughout this Quarterly Report on Form 10-Q, "Agios," "the company," “we,” “us,” and “our,” and similar expressions, except where the context requires otherwise, refer to Agios Pharmaceuticals, Inc. and its consolidated subsidiaries, and “our Board of Directors” refers to the board of directors of Agios Pharmaceuticals, Inc.OverviewWe are a biopharmaceutical company committed to transforming patients’ lives through leadership in the field of cellular metabolism, with the goal of creating differentiated medicines for rare diseases, with a focus on classical hematology. With a history of focused study